Application of sorafenib combined auranofin in preparation of medicine for treating liver cancer
A technology for treating liver cancer and inhibiting liver cancer, applied in the field of medicine, can solve the problems of low success rate, expensive and time-consuming new drug development and registration, and no auranofin liver cancer treatment, so as to improve the effect of inhibiting liver cancer
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0025] Embodiment 1, the combined drug regimen for the treatment of liver cancer
[0026] 1. Drug sensitivity
[0027] HepG2 and MHCC-97H liver cancer cells were inoculated in 96-well plates, and after adhering to the wall overnight, a series of drugs from high to low concentrations were prepared, and a control group was set up, with 3 replicate wells for each concentration. After incubation in the cell culture box for 48 hours, the proliferation of the cells was monitored with a cell dynamic detector (escolifesciences, CCL-170T-8), and the cell growth curve was drawn. The therapeutic concentrations of Sorafenib (Sora for short) and Auranofin (Aura for short) in HepG2 cells were: 5 μM and 0.4 μM respectively, and the therapeutic concentrations of Sorafenib and Auranofin in MHCC-97H cells were: 7 μM , 0.6μM (such as figure 1 Middle A-B).
[0028] 2. Cell growth curve
[0029] As we all know, auranofin is a thioredoxin reductase (TrxR) inhibitor, and TrxR belongs to the thio...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


